The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor <i>In Vitro</i> and Confer Resistance To Nirmatrelvir
Dirk Jochmans, Liu C, Kim Donckers, Antitsa Stoycheva, Sandro Boland, Sarah Stevens, Chloe De Vita, Bert Vanmechelen, Piet Maes, Bettina Salome Trüeb, Nadine Ebert, Volker Thiel, Steven De Jonghe, Laura Vangeel, Dorothée Bardiot, Andreas Jekle, Lawrence M. Blatt, Leonid Beigelman, Julian Symons, Pierre Raboisson, Patrick Chaltin, Arnaud Marchand, Johan Neyts, Jérôme Deval, Koen Vandyck
Abstract
antiviral resistance development may be predictive for the clinical situation. Therefore, our work will be important for the management of COVID-19 with Paxlovid and next-generation SARS-CoV-2 3CLpro inhibitors.
Topics & Concepts
ProteaseContext (archaeology)EnzymeDrug resistanceIn vitroBiologyProtease inhibitor (pharmacology)MutantDrugVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)VirusBiochemistryGenePharmacologyMicrobiologyViral loadMedicineInfectious disease (medical specialty)Antiretroviral therapyPathologyDiseasePaleontologySARS-CoV-2 and COVID-19 ResearchMosquito-borne diseases and controlComputational Drug Discovery Methods